Compounded GLP-1 adverse-event reports: how to interpret FDA’s 2026 counts

01

The current FDA counts and their date

FDA’s current concerns page states that, as of May 31, 2026, the agency had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The page was current as of June 15, 2026 when checked for this analysis.

Those numbers need the date and the word associated. FDA says it is not always possible to determine whether the adverse event resulted from the drug or whether other factors contributed. A report can name a suspect product without establishing that it caused the event.

The counts should not be added to approved-product reports, divided by estimated users, or compared as rates without a valid exposure denominator and careful case review. They are surveillance inputs that can help FDA look for patterns.

02

Why an adverse event is not automatically an adverse drug reaction

FDA distinguishes an adverse event from an adverse drug reaction. An adverse event is a medical occurrence after a person takes a drug regardless of whether the drug caused it. An adverse drug reaction is a harmful and unintended response determined to be caused by the drug.

FDA reviewers use report details and other evidence to investigate potential signals. They may remove duplicate reports, apply consistent case definitions, evaluate timing and alternative explanations, and use other data sources. The public dashboard alone does not contain all narrative fields available to FDA reviewers.

A high report count can reflect product use, publicity, reporting requirements, litigation, stimulated reporting, duplicate submissions, or a real safety issue. A low count can reflect limited use or underreporting. Neither direction supports a simple safety ranking.

03

The new AEMS dashboard has important limitations

FDA launched the Adverse Event Monitoring System, or AEMS, public dashboard in March 2026 to consolidate reporting systems and make reports easier to search. The system replaces the former FAERS name for this public interface and is intended to improve access and signal detection.

FDA lists four central limitations: duplicate and incomplete reports exist; a report does not establish causation; report information may not be medically verified; and reports cannot establish how often an event occurs. FDA also says patients should talk with their clinician before stopping or changing a medication.

A consumer search should therefore preserve the drug name, product type, reporting dates, and search date and should be described as a report count. Do not label dashboard results as confirmed cases, clinical-trial outcomes, or an incidence percentage.

04

Why compounded GLP-1 reporting may be incomplete

FDA says federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA. The agency therefore considers adverse events involving compounded versions likely underreported. That reporting gap makes a direct comparison with approved products especially unreliable.

Compounded products also vary by compounder, concentration, container, instructions, ingredient source, shipping process, and patient-specific circumstances. A report attributed only to semaglutide or tirzepatide may lack the product identity needed to connect it to one facility or formulation.

This does not mean every compounded product is defective. It means the available spontaneous-report count is not a controlled study of all compounded products and cannot establish a class-wide event rate.

05

What FDA’s accompanying concerns add to the picture

FDA has described reports involving dosing errors with compounded injectable semaglutide, including confusion in measurement and calculation. The agency has also received complaints that some compounded injectable GLP-1 products arrived warm or with inadequate refrigeration, and it has identified fraudulent labels naming nonexistent pharmacies or pharmacies that denied making the product.

The same FDA page warns about semaglutide salt forms that differ from the active ingredient used in approved products. It also distinguishes compounded products from counterfeit and illegally marketed research-use products. These are separate risk pathways and should not be blended into one statistic.

When evaluating a report or a provider claim, identify the exact product, pharmacy, ingredient form, concentration, lot, storage history, instructions, and event timing. Those details are more useful than a molecule-level count alone.

06

How consumers can use the information responsibly

Use the FDA counts as a prompt for verification. Confirm that a prescription is filled by a state-licensed pharmacy, compare the received label with the expected pharmacy and product, preserve packaging and shipping materials, and contact the prescriber or pharmacist when important information conflicts.

If a product problem or adverse event occurs, FDA’s MedWatch program accepts reports from patients, consumers, and health professionals. A detailed report can include the product label, lot, dates, pharmacy, prescriber, shipping condition, administration details, and relevant medical evaluation without publishing private health information in a directory.

Do not use this article or an AEMS search to diagnose a reaction or decide whether to start, stop, or change a medication. Contact an appropriately licensed clinician or pharmacist for medical questions and seek urgent care for an emergency.

• →Date every report count and dashboard query.
• →Use “reported” or “associated,” not “caused,” unless a source establishes causation.
• →Do not calculate incidence without reliable exposure data.
• →Separate approved, compounded, counterfeit, and research-use products.
• →Report suspected problems through the appropriate safety channel.